Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Consolidation treatment with Y-90 ibritumomab tiuxetan in high-risk follicular lymphoma after R-CHOP
2007-003091-19Phase 2Completed
- Sponsor
- GOTEL
- Start
- Aug 2007
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ibritumomab tiuxetan in follicular lymphoma (FL), sponsored by GOTEL. Primary endpoint: Complete clinical response rate. Started Aug 2007; status: completed.
02
Drugs
ibritumomab tiuxetan
03
Conditions
follicular lymphoma (FL)
Beyond the preview
Go deeper on 2007-003091-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-003091-19.